Where the summer COVID-19 infections are hitting hardest
COVID-19 is trending up in many Mid-Atlantic, Southeast, Southern, and West Coast states. The agency said infections are 'growing or likely growing' in 40 states, based on emergency department visit data as of July 29. Infections were unchanged in nine states.
The weekly percentage of emergency department visits among people diagnosed with COVID-19 is low, but growing, CDC said. Visits were highest for children younger than 4 years old, which experts said makes sense because many remain unvaccinated.
WastewaterSCAN, which monitors infectious diseases through municipal wastewater systems, categorized national coronavirus levels as 'high' and trending upward since mid-July.
According to CDC, the wastewater viral activity level for coronavirus is currently low, and only Alabama, Florida, Kentucky, Louisiana, California, Alaska and Texas reported 'high' or 'very high' levels.
Experts say a lack of data is making it harder to track COVID-19 in real time, but the available information indicates the expected seasonal wave is happening.
Ever since 2020, COVID-19 has peaked twice a year. Cases rise in the winter and drop into the spring, and then again in the summer as travel peaks and people seek air-conditioned indoor spaces away from the heat.
While other respiratory viruses remain at low levels until the winter, experts have said COVID-19's ability to mutate sets it apart and contributes to a much higher baseline infection rate. More cases circulating year-round means more opportunities for the virus to mutate.
The vaccine being updated for the coming fall season is targeted to the JN.1 variant, as it was last year. But Health and Human Services Secretary Robert F. Kennedy Jr. has significantly narrowed recommendations on who should get the vaccine, raising significant questions about the availability and affordability come the fall.
In May, Kennedy said the shots would no longer be recommended for healthy kids, a decision that health experts have said lacks scientific basis. A coalition of medical groups subsequently sued over the move.
In addition, a new policy requires all updated COVID-19 vaccines to undergo extensive placebo-controlled clinical trials, as if it were a new shot rather than an update to one that already exists.
The updated Covid shots are expected to be available in the fall to adults 65 and up and kids and adults with at least one medical condition that puts them at risk for severe illness — the groups exempt from the clinical trial requirement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
17 minutes ago
- Newsweek
Trump Brushes Off Major Success From First Term: 'Long Time Ago'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump on Wednesday brushed off what is widely considered to be among the biggest uncontested successes of his first term while reacting to Health and Human Services Secretary Robert F. Kennedy Jr.'s move to pull $500 million in funding for next-generation mRNA-based vaccines to tackle viruses like Covid, H5N1 and the flu. "You were the driving force behind Operation Warp Speed, these mRNA vaccines that are the gold standard," a reporter asked Trump during a White House event on Wednesday. Operation Warp Speed was a 2020 public-private partnership, initiated by the first Trump administration, aimed at accelerating the development and distribution of a COVID-19 vaccine. At the time, it was almost universally accepted that an effective vaccine for the coronavirus was at least 18 months to two years away. Trump's operation did it in less than a year. "Now, your health secretary is pulling back all the funding for research, he's saying that the risks outweigh the benefits, which puts him at odds with the entire medical community, and with you," the reporter continued. "What's going on?" "Research on what?" Trump asked. "Into mRNA vaccines," she clarified. "Well, we're going to look at that," the president replied. "We're talking about it and they're doing a very good job, and you know, that is a pass." Trump went on to briefly acknowledge the success of Operation Warp Speed before dismissing it. "Operation Warp Speed was, whether you're a Republican or Democrat, considered one of the most incredible things ever done in this country," the president said. "The efficiency, the way it was done, the distribution, everything about it has been amazing." Then he added: "But, you know, that was now a long time ago. And we're onto other things, but we are speaking about it. We have meetings about it ... we're looking for other answers to other problems, to other sicknesses and diseases and I think we're doing really well." This is a breaking news story. Updates to follow.
an hour ago
RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?
The Department of Health and Human Services (HHS) announced this week it is beginning a "coordinated wind-down" of federally funded mRNA vaccine development. This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment projects worth nearly $500 million. While some final-stage contracts will be allowed to be completed, no new mRNA-based projects will be initiated, the HHS said. "We reviewed the science, listened to the experts, and acted," Secretary Robert F. Kennedy Jr. said in a press release on Tuesday. "The data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." Infectious disease experts told ABC News that mRNA technology has been very successful in preventing severe disease, hospitalization and deaths, especially during the COVID-19 pandemic, potentially affecting our preparedness for future pandemics. Ending mRNA vaccine development may also squash enthusiasm for technology that has been hailed as a potential promise for cancer and HIV vaccines. "It's an excellent technology. It saved millions of lives and did it in a remarkably safe manner," Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, told ABC News. "I think it's an unscientific move, a move that goes against existing science." Affecting future pandemic preparedness Last year, the federal government awarded Moderna $176 million to help expedite the development of an mRNA-based bird flu vaccine. Earlier this year, the vaccine manufacturer received an additional $590 million to speed up the development. However, in its press release, the HHS said it was cancelling the award, which has been issued by the Biomedical Advanced Research and Development Authority, to Moderna and the University of Texas Medical Branch. Dr. Peter Hotez, a professor of pediatrics and molecular virology at Baylor College of Medicine in Houston, told ABC News the wind-down is a blow to pandemic preparedness. During the COVID-19 pandemic, mRNA technology demonstrated its ability to scale up vaccine production quickly. "The message to the companies will clearly be that they can no longer rely on the U.S. government for supporting any mRNA vaccine work, which is unfortunate, or even tragic, because the mRNA platform is one of the few that we have for pandemic threats in terms of something that we can make a vaccine for very quickly," he said. "So what, what Mr. Kennedy's and HHS' actions are doing is weakening our pandemic preparedness and weakening our biosecurity." The HHS also said it was terminating contracts with Emory University and Tiba Biotech. Researchers had been working on using mRNA technology to develop a nasal influenza vaccine. Emory has also been working on a dry powder inhaled mRNA-based treatment for influenza and COVID with TFF Pharmaceuticals, funded by BARDA. It's unclear if this is one of the 22 contracts that have been canceled. Hotez said COVID-19 and influenza can have very severe consequences and that it's incorrect for Kennedy to mischaracterize them as harmless upper respiratory infections. "COVID and flu are not [only] upper respiratory infections," he said. "The reason we develop vaccines for COVID and flu is because they cause systemic illness and lower respiratory infections and cardiovascular illness. … This is part of the anti-vaccine playbook, to diminish the severity of the illness, and to say something like influenza or COVID is an upper respiratory infection, it's just very, very misleading." Cancer vaccines, HIV treatments mRNA technology has also been hailed as a potential vector for providing personalized cancer treatments and protection against HIV transmission. In February, a small preliminary study published in the journal Nature found a personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery. Additionally, a University of Florida study found an experimental mRNA vaccine paired with anticancer drugs boosted an anti-tumor response. Meanwhile, earlier this month, an early-stage clinical trial found two mRNA vaccine candidates triggered a strong immune response against HIV. Results from the trial showed that 80% of participants who received one of two vaccine candidates produced antibodies. Although antiretroviral therapy has been the standard treatment for HIV infection, and is effective in preventing transmission, it is hard to scale up worldwide due to its costs, making mRNA vaccines to be anti-HIV vaccine strategy, researchers from the U.S., Germany and Romania wrote in a commentary in June 2022. It's unclear if any of the BARDA contracts are specifically for cancer vaccines or HIV vaccine development, but Hotez said the real damage is denigrating mRNA technology. "What he's done is he's caused uncertainty among the American people about the safety and effectiveness of mRNA for any condition, including cancer," he said. "And in fact, mRNA technology is probably the most exciting technology we have now for cancer and also other non-communicable illnesses. … Even though he may not be canceling any cancer vaccine contracts through BARDA, it may have collateral deleterious in terms of squashing enthusiasm for the technology." Offit added that mRNA is not brand-new technology. mRNA was discovered independently by two teams in 1961, including French and American molecular biologists. Breakthroughs in developing mRNA vaccines began in the early 2000s, eventually leading to the development of COVID-19 vaccines in 2020. This makes the technology primed for being used in other avenues, such as cancer vaccines, Offit said. "We now know a lot about mRNA," he said. "We know a lot about its safety. We know a lot about its safety in young children, including babies. We know a lot about it regarding gene therapy. We know a lot about this safety in terms of pregnant people, where that's often not the case with new technology." Offit went on, "So you have this background of information that enables you to move forward in a number of areas, involving babies or involving pregnant women. But there was an attempt by this administration to squelch that, to sit on all that for no good reason other than a political reason."
Yahoo
an hour ago
- Yahoo
What to know about chikungunya virus in China as US issues travel alert
The U.S. Centers for Disease Control and Prevention has issued a travel warning following an outbreak of a mosquito-borne illness called chikungunya in China. The CDC's warning centers on Guangdong Province, where the outbreak has exceeded 7,000 confirmed cases since June 2025, according to Chinese health officials. The outbreak in Guangdong Province has been linked to monsoon flooding, which created ideal breeding conditions for mosquitoes, which spread the virus that causes chikungunya. In the new travel warning, the CDC emphasized that vaccination is available and recommended for travelers. Dr. Todd Ellerin, chief of infectious disease at South Shore Health in Massachusetts, told ABC News that travelers to the region "should absolutely take precautions" against the illness. "Wear long sleeves and pants, use insect repellent with DEET, and use mosquito netting for babies too young for repellent," said Ellerin, who is not affiliated with the CDC. Here is what to know about the illness. How common is chikungunya? Chikungunya is not a new infection. It has been around since the 1950s, with outbreaks more commonly seen in tropical areas in recent decades. Globally, there have been about 240,000 infections since the start of 2025, according to the European Centre for Disease Prevention and Control. Chikungunya is not common in the United States. The CDC says there have not been any reported locally acquired cases since 2019. What are the symptoms of chikungunya? According to the CDC, common symptoms of the virus include sudden-onset high fever, severe joint pain (especially in the hands, wrists, ankles, and feet), muscle pain, headache, fatigue and skin rash. Georgia woman describes crippling pain of chikungunya virus Most people recover without medical intervention within seven to 10 days, but in some cases, symptoms can persist for weeks or months. What is the incubation period for chikungunya? Chikungunya typically has an incubation period of less than one week, according to Ellerin. "If it's been more than a week since you left a high-risk area, you're likely in the clear," he said. How is chikungunya treated? There is no specific antiviral treatment for chikungunya. Instead, care focuses on relieving symptoms while the body recovers. The CDC recommends rest, fluids, and medications like acetaminophen for pain and fever. NSAIDs may be used once dengue, another mosquito-borne disease, has been ruled out. Deaths from chikungunya are rare, according to the CDC. Is there a vaccine for chikungunya? There are two vaccines available in the U.S. that begin offering protection within about two weeks of a single dose. Cases of mosquito-borne viruses on the rise The CDC recommends vaccination for travelers visiting areas with active outbreaks, people spending extend time abroad -- typically six months or longer -- and laboratory workers who handle the virus. What contributes to the spread of chikungunya? Climate change is a major driver of chikungunya's global spread. "Warmer temperatures and increased rainfall are helping Aedes mosquitoes expand into new regions," Dr. Krutika Kuppalli of the division of infectious diseases at the University of Texas Southwestern Medical Center told ABC News. Veer Patel, M.D., is an emergency medicine doctor at Maimonides Medical Center and a member of the ABC News Medical Unit. Solve the daily Crossword
